Applications
-
WB
-
IHC-P
-
FC
-
IP
REACTIVITY
-
Human
-
Mouse
SPECIFICATIONS
Product Type
Recombinant Rabbit monoclonal primary
Product Name
Recombinant Biglycan Monoclonal Antibody (ET7107-48)
Immunogen
Recombinant protein
Host
Rabbit
Positive Control
HepG2, human kidney tissue, mouse heart tissue, human skin tissue lysates.
Conjugation
Unconjugated
Clonality
Monoclonal
Clone Number
JB71-31
PROPERTIES
Form
Liquid
Storage Condition
Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.
Storage Buffer
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Concentration
1 ug/ul
PURIFICATION
Protein A purified.
MOLECULAR WEIGHT
42 kDa
Isotype
IgG
APPLICATION DILUTION
-
WB
-
1:500-1:1000
-
IHC-P
-
1:50-1:200
-
FC
-
1:50-1:100
TARGET
UNIPROT #
PROTEIN NAME
Biglycan
SYNONYMS
BGN antibody; Biglycan antibody; Biglycan proteoglycan antibody; Bone/cartilage proteoglycan I antibody; Dermatan sulphate proteoglycan I antibody; DSPG1 antibody; PG S1 antibody; PG-S1 antibody; PGI antibody; PGS1_HUMAN antibody; SEMDX antibody; SLRR1A antibody; Small leucine rich protein 1A antibody
SEQUENCE SIMILARITIES
Belongs to the small leucine-rich proteoglycan (SLRP) family. SLRP class I subfamily.
TISSUE SPECIFICITY
Found in several connective tissues, especially in articular cartilages.
POST-TRANSLATIONAL MODIFICATION
The two attached glycosaminoglycan chains can be either chondroitin sulfate or dermatan sulfate.
SUBCELLULAR LOCATION
Extracellular matrix. Secreted.
FUNCTION
Biglycan, a class I small leucine rich proteoglycan (SLRP) present in the extracellular matrix, influences bone cell differentiation and proliferation. Biglycan contains two chondroitin sulfate glucosaminoglycan (GAG) chains attached near its amino terminus, whereas a closely related SLRP, decorin, contains only one. Biglycan deficient specimens possess diminished capacity to produce bone cells precursors, a lessened response to TGFβ, reduced collagen synthesis, and increased apoptosis. Patients with rheumatoid arthritis express increased immunity to biglycan whereas osteoarthritis patients do not, suggesting that higher immunity to SLRPs may play a role in the pathogenesis of inflammatory rheumatic diseases.